Enlivex Therapeutics

ENLV NASDAQ
17.50
-0.30
-1.69%
Closed 16:00 06/18 EDT
Open
17.80
Prev Close
17.80
High
20.48
Low
16.96
Volume
39.56K
Avg Vol (3M)
12.62K
52 Week High
20.48
52 Week Low
6.19
% Turnover
0.39%
Market Cap
177.00M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Enlivex Therapeutics ENLV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
MORE >

Recently

Name
Price
%Change